Are hyaluronic acid knee injections worth the cost for you

In the UK, hyaluronic acid (HA) knee injections can help some people with osteoarthritis, but the average benefit is usually modest and temporary—often measured in months rather than years—so “worth it” tends to hinge on symptom severity, osteoarthritis stage and willingness to self-fund. HA is a natural component of synovial fluid, and injections aim to “top up” lubrication and shock absorption; they do not regrow cartilage or reverse structural joint damage.

Evidence syntheses (including a 2025 umbrella review) generally find HA provides moderate improvements in pain and function versus placebo/saline, with the clearest signal in early-to-moderate knee osteoarthritis, and an overall good safety profile—yet effect sizes are not large enough for some health systems to see it as cost-effective for routine use.

That tension shows up clearly in UK policy. NICE guideline NG226 says not to offer intra‑articular hyaluronan for osteoarthritis, and the NHS England 2023 decision aid states that hyaluronic acid injections “do not help with knee osteoarthritis”. Local commissioning policies can be even more explicit: for example, a 2023 Cheshire and Merseyside ICB policy says intra‑articular hyaluronan is not routinely commissioned for peripheral joints.

Private prices are typically in the hundreds of pounds per knee (often quoted around £250–£850 per joint), and costs can vary with the product used, clinician expertise and whether ultrasound guidance is included. In the wider injection landscape, HA sits alongside corticosteroid injections (often used first-line on the NHS) and private options such as PRP or other injectables; a 2024 network meta-analysis found PRP and BMAC tend to rank higher than HA on pain and function on average.

How NHS and private access usually work in the UK

Can it be done on the NHS?

NICE guideline NG226 advises against using intra‑articular hyaluronan as routine osteoarthritis care, and many local NHS commissioners follow that line when deciding what to fund. For example, a 2023 Cheshire and Merseyside ICB commissioning policy states that intra‑articular hyaluronan is “not routinely commissioned” for peripheral joints such as the knee, which in practice makes NHS access uncommon outside exceptional funding requests or research settings.

What the NHS is more likely to offer instead

NHS pathways for knee pain and osteoarthritis typically focus on supported self‑management and rehabilitation first (for example, advice, physiotherapy-led exercise programmes, weight support and medicines), with escalation to options such as corticosteroid injections in many areas and orthopaedic referral where symptoms and findings warrant it.

How private access commonly works

Private care is usually arranged as an outpatient, ultrasound‑guided injection pathway: an initial assessment (often self‑referral, sometimes supported by a GP or community MSK letter), confirmation of osteoarthritis severity, and discussion of alternatives before scheduling hyaluronic acid or another injection. UK clinic guidance also notes that insurance funding can be variable, with restrictions depending on the policy terms.

What to expect from an ultrasound-guided HA knee injection

An ultrasound‑guided HA knee injection is an outpatient procedure (not an operation) that places a gel containing hyaluronic acid into the knee joint to support lubrication and shock absorption in synovial fluid.

Before the appointment

Clinics typically start with a short screening: past medical history, current medicines (including blood thinners), allergy checks, and a review of any recent scans or previous knee injections or surgery. The aim is to confirm the knee joint is the right target and to reduce avoidable risks before the day.

During the injection

After consent, the clinician usually performs a focused knee examination and an ultrasound scan to identify the joint space and look for issues such as a large effusion. The skin is cleaned with antiseptic, local anaesthetic is used to numb the area, and then a single needle is guided into the joint while the needle tip is seen in real time on the ultrasound screen. The HA gel (for example, products such as Ostenil Plus are used in some clinics) is injected slowly; common sensations are a brief sting from anaesthetic and pressure during the gel injection.

After you leave

Most people can walk out soon after. The most common after‑effects are short‑lived soreness or swelling around the injection site; larger reviews describe IAHA as generally well tolerated, with serious complications such as infection reported rarely. Benefit is often not immediate, so follow‑up plans are commonly set for a later review (for example, in the weeks to months after injection) to judge response and decide next steps.

Single-shot versus a series of HA injections

The choice between a single HA injection and a short course is not just about convenience; it reflects how different products behaved in studies published over the past decade.

In a 2017 systematic review and meta-analysis of 30 trials, regimens using 2–4 injections produced the largest average pain reductions at 3 and 6 months. In contrast, single-injection regimens in those older studies often did not show a significant advantage over saline at the same time-points; courses of ≥5 injections were effective but had higher rates of treatment-related adverse events than saline.

More recent work complicates the older “more injections = better” assumption. A 2026 double-blind multicentre RCT (n=347) reported large reductions in WOMAC walking pain after a single high–molecular-weight injection, with improvements maintained to 26 weeks. A smaller 2025 non-randomised study (n=40) also reported symptom improvements over 30–60 days after one highly concentrated injection.

Head-to-head comparisons still sometimes favour a series: a 2024 clinical study found a three-injection low-dose protocol produced better WOMAC/VAS/Lequesne improvements than a single higher-dose injection.

Formulation appears to matter as much as schedule: a Bayesian network meta-analysis (n=9,822) found high and ultra-high molecular-weight HA performed best for pain at around 4–6 months, while low-molecular-weight HA performed worst.

• Single shot: fewer appointments; potentially lower disruption and cost (private UK pricing commonly cited at roughly £250–£850 per joint); but it is a bigger “all-in” bet on one dose.
• Short series (2–4): more visits and cumulative cost; but there is flexibility to stop early if response or tolerability is poor.

A practical minimum is clarity on the exact HA product (including molecular weight), dose and schedule being proposed, and how this fits alongside other injectables sometimes discussed for knee OA (for example, polyacrylamide hydrogel).

Who is most likely to benefit from HA knee injections

Timing tends to shape expectations. A 2025 umbrella review of knee osteoarthritis research found intra‑articular hyaluronic acid (HA) gives modest average improvements in pain and function, with benefits most apparent in early‑to‑moderate disease rather than very advanced, “bone‑on‑bone” joints on imaging. In that context, HA is usually framed as symptom support, not a structural fix.

Patient selection guidance also points in the same direction. The EUROVISCO expert consensus (2025) describes viscosupplementation as something that may be considered when symptoms are affecting day‑to‑day life, simpler measures have already been tried, and there is a wish to delay arthroplasty. In the same document, obesity and advanced radiographic osteoarthritis are highlighted as the two main predictors of a poorer response—often meaning the average change is smaller and harder to notice, rather than implying “no chance” of benefit.

Observational data suggest the same “earlier is better” pattern: in a prospective study of people with Kellgren–Lawrence grade I–II knee OA, Knee Society scores improved at 12 months, with larger gains reported in grade I than grade II disease.

• Often a better fit: mild-to-moderate X‑ray changes (for example, KL I–II), symptoms limiting walking or stairs, a goal of staying active, and a plan to continue strength work and load management.
• Often a poorer fit: end‑stage OA with marked deformity/instability, significant obesity, or expecting a complete cure from a single injection.

Other injectables (such as PRP, BMAC, or polyacrylamide hydrogel) may offer different trade‑offs in cost, evidence base, and durability, so expected response is usually best judged in a clinician-led discussion that weighs imaging stage, body weight, symptoms, and prior injection history together.

Questions to ask before booking a private HA injection

Before paying for a private hyaluronic acid (HA) injection, it helps to pin down the basics that sit behind the UK’s cautious stance (for example, NICE NG226 and the 2023 NHS England decision aid).

Is HA the right choice for my knee?

• What stage is the osteoarthritis on imaging (for example, Kellgren–Lawrence grade), and does that change the likelihood of benefit?
• Have key non-injection options already been optimised (structured strength exercise, weight management, and simple pain relief)?
• Why HA in my case rather than a steroid injection, PRP, polyacrylamide hydrogel, or no injection—given NICE NG226 advises against routine intra‑articular hyaluronan for OA?

What exactly is being offered?

• Which HA product is being used (including molecular weight), and what evidence supports that specific formulation?
• Is this a single injection or a 2–4 injection course, and what data supports that schedule for someone with my OA stage?
• Is ultrasound guidance included, and who performs the scan and injection on the day?

Costs, follow-up, and safety planning

• What is the total price for the whole pathway (assessment, ultrasound guidance, and follow-up), and are repeat courses expected (for example, within 6–12 months)?
• How will “worked” be defined (for example, a change in walking pain or a score such as WOMAC) and at what review point (for example, 12 and 26 weeks)?
• What are the common after-effects (temporary pain/swelling) and rare risks (infection), and who should be contacted if the knee becomes very painful, hot, or markedly swollen the same day or overnight?

1. [1] Single-injection hyaluronic acid treatment demonstrates non-inferiority in the relief of symptomatic knee osteoarthritis: A randomized double-blind, multi-center controlled study. (2026). https://doi.org/10.1016/j.ocarto.2026.100752 https://doi.org/10.1016/j.ocarto.2026.100752
2. [2] Single Injection of Highly Concentrated Hyaluronic Acid Provides Improvement of Knee Joint Arthrokinematic Motion and Clinical Outcomes in Patients with Osteoarthritis—Non-Randomized Clinical Study. (2025). https://doi.org/10.3390/jcm14103557 https://doi.org/10.3390/jcm14103557
3. [3] Intra-Articular Hyaluronic Acid for Knee Osteoarthritis: A Systematic Umbrella Review. (2025). https://doi.org/10.3390/jcm14041272 https://doi.org/10.3390/jcm14041272
4. [4] Comparison of Different Molecular Weights of Intra-Articular Hyaluronic Acid Injections for Knee Osteoarthritis: A Bayesian Network Meta-Analysis. (2025). https://doi.org/10.3390/biomedicines13010175 https://doi.org/10.3390/biomedicines13010175
5. [5] Platelet Rich Plasma, Bone Marrow Aspirate Concentrate and Hyaluronic Acid Injections Outperform Corticosteroids ...: A Systematic Review and Network Meta-Analysis. (2024). https://doi.org/10.1016/j.arthro.2024.01.037 https://doi.org/10.1016/j.arthro.2024.01.037